Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (GLUE) management will participate in four investor conference fireside chats in November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monte Rosa Therapeutics (GLUE) management will participate in four investor conference fireside chats in November and December 2026.
The schedule includes Guggenheim on November 9 at 8:00 a.m. ET, UBS on November 16 at 12:00 p.m. GMT, Jefferies on November 17 at 10:00 a.m. GMT, and Piper Sandler on December 1 at 3:30 p.m. ET. Webcasts will be available through the company's website, with archives available for 30 days following the presentations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ET
- UBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. GMT
- Jefferies Global Healthcare Conference in London – fireside chat, November 17, 2026, at 10:00 a.m. GMT
- Piper Sandler 38th Annual Healthcare Conference (New York, NY) – fireside chat, December 1, 2026, at 3:30 p.m. ET
Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
